Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand

Chutima Suraratdecha, Robyn M Stuart, Chomnad Manopaiboon, Dylan Green, Cheewanan Lertpiriyasuwat, David P Wilson, Patcharaporn Pavaputanon, Prin Visavakum, Patama Monkongdee, Thana Khawcharoenporn, Phiphatthananon Tharee, Chonticha Kittinunvorakoon, Michael Martin, Chutima Suraratdecha, Robyn M Stuart, Chomnad Manopaiboon, Dylan Green, Cheewanan Lertpiriyasuwat, David P Wilson, Patcharaporn Pavaputanon, Prin Visavakum, Patama Monkongdee, Thana Khawcharoenporn, Phiphatthananon Tharee, Chonticha Kittinunvorakoon, Michael Martin

Abstract

Introduction: In 2014, the Government of Thailand recommended pre-exposure prophylaxis (PrEP) as an additional HIV prevention programme within Thailand's National Guidelines on HIV/AIDS Treatment Prevention. However, to date implementation and uptake of PrEP programmes have been limited, and evidence on the costs and the epidemiological and economic impact is not available.

Methods: We estimated the costs associated with PrEP provision among men having sex with men (MSM) participating in a facility-based, prospective observational cohort study: the Test, Treat and Prevent HIV Programme in Thailand. We created a suite of scenarios to estimate the cost-effectiveness of PrEP and sensitivity of the results to the model input parameters, including PrEP programme effectiveness, PrEP uptake among high-risk and low-risk MSM, baseline and future antiretroviral therapy (ART) coverage, condom use, unit cost of delivering PrEP, and the discount rate.

Results: Drug costs accounted for 82.5% of the total cost of providing PrEP, followed by lab testing (8.2%) and personnel costs (7.8%). The estimated costs of providing the PrEP package in accordance with the national recommendation ranges from US$223 to US$311 per person per year. Based on our modelling results, we estimate that PrEP would be cost-effective when provided to either high-risk or all MSM. However, we found that the programme would be approximately 32% more cost-effective if offered to high-risk MSM than it would be if offered to all MSM, with an incremental cost-effectiveness ratio of US$4,836 per disability-adjusted life years (DALY) averted and US$7,089 per DALY averted respectively. Cost-effectiveness acceptability curves demonstrate that 80% of scenarios would be cost-effective when PrEP is provided solely to higher-risk MSM.

Conclusion: We provide the first estimates on cost and cost-effectiveness of PrEP in the Asia-Pacific region, and offer insights on how to deliver PrEP in combination with ART. While the high drug cost poses a budgeting challenge, incorporating PrEP delivery into an existing ART programme could be a cost-effective strategy to prevent HIV infections among MSM in Thailand.

Trial registration: ClinicalTrials.gov NCT02369887.

Keywords: AIDS; HIV; Thailand; cost; cost-effectiveness analysis; modelling; pre-exposure prophylaxis.

© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Tornado diagrams of univariate sensitivity analysis.
Figure 2
Figure 2
Cost‐effectiveness acceptability curve for pre‐exposure prophylaxis strategies.

References

    1. World Health Organization . WHO expands recommendation on oral pre‐exposure prophylaxis of HIV infection (PrEP). Policy brief. Geneva: World Health Organization; 2015. [cited 14 December 2017]. Available from:
    1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet. 2013;381:2083–90.
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.
    1. Bernard CL, Brandeau ML, Humphreys K, Bendavid E, Holodniy M, Weyant C, et al. Cost‐effectiveness of HIV preexposure prophylaxis for people who inject drugs in the United States. Ann Intern Med. 2016;165:10–9.
    1. Nichols BE, Boucher CAB, van der Valk M, Rijnders BJA, van de Vijver DAMC. Cost‐effectiveness analysis of pre‐exposure prophylaxis for HIV‐1 prevention in the Netherlands: a mathematical modelling study. Lancet Infect Dis. 2016;16(12):1423–9.
    1. Ying R, Sharma M, Heffron R, Celum CL, Baeten JM, Katabira E, et al. Cost‐effectiveness of pre‐exposure prophylaxis targeted to high‐risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. J Int AIDS Soc. 2015;18(4 Suppl 3):20013.
    1. Chen A, Dowdy DW. Clinical effectiveness and cost‐effectiveness of HIV pre‐exposure prophylaxis in men who have sex with men: risk calculators for real‐world decision‐making. PLoS ONE. 2014;9(10):e108742.
    1. Department of Disease Control, Thailand Ministry of Public Health . HIV/AIDS treatment and prevention. Nonthaburi: Ministry of Public Health; 2014.
    1. Thailand Ministry of Public Health . National Operational Plan for Ending AIDS 2015–2019. Nonthaburi: Thailand Ministry of Public Health; 2014.
    1. Phanuphak N. PrEP uptake and adherence: experiences from Thailand PrEP programs, in prepping men who have sex with men for better health outcomes: a conversation between healthcare providers and their clients, the 9th IAS conference on HIV science; 23–26 July 2017; Paris.
    1. Colby D, Kongkabpan M, Teeratakulpisarn S, Teeratakulpisarn N, Pondet C, Pakam C, et al., Safety and efficacy of tenofovir disoproxil fumarate plus emtricitabine for HIV pre‐exposure prophylaxis in Thailand, in Asia Pacific conference on AIDS and co‐infections; 2016: Hong Kong.
    1. Colby D, Srithanaviboonchai K, Vanichseni S, Ongwandee S, Phanuphak N, Martin M, et al. HIV pre‐exposure prophylaxis and health and community systems in the Global South: Thailand case study. J Int AIDS Soc. 2015;18(4 Suppl 3):19953.
    1. Bureau of AIDS, TB and STIs, Thailand Ministry of Public Health . Evaluation of a facility‐based test, treat, and prevent HIV program among men who have sex with men and transgender women in Thailand. Nonthaburi: Thailand Ministry of Public Health; 2016.
    1. Kerr CC, Stuart RM, Gray RT, Shattock AJ, Fraser‐Hurt N, Benedikt C, et al. Optima: a model for HIV epidemic analysis, program prioritization, and resource optimization. J Acquir Immune Defic Syndr. 2015;69(3):365–76.
    1. Stuart RM, Kerr CC, Haghparast‐Bidgoli H, Estill J, Grobicki L, Baranczuk Z, et al. Getting it right when budgets are tight: using optimal expansion pathways to prioritize responses to concentrated and mixed HIV epidemics. PLoS ONE. 2017;12(10):e0185077.
    1. UNAIDS, key population Atlas. AIDSinfo. (accessed January 31, 2018).
    1. Zhang L, Phanuphak N, Henderson K, Nonenoy S, Srikaew S, Shattock AJ, et al. Scaling up of HIV treatment for men who have sex with men in Bangkok: a modelling and costing study. Lancet HIV. 2015;2(5):e200–7.
    1. Peerapatanapokin W. Estimated sizes of men who have sex with men (MSM). Paper presented at: Ministry of Public Health Stakeholders Seminar on Size Estimation; 2012. Jan 10; Nonthaburi, Thailand.
    1. The Optima Consortium for Decision Science .Volume VI: Parameter data sources. In: Optima HIV User Guide 2018 [Cited 16 April 2018 ] Available from: .
    1. van Griensven F, Varangrat A, Wimonsate W, Tanpradech S, Kladsawad K, Chemnasiri T, et al. Trends in HIV prevalence, estimated HIV incidence, and risk behavior among men who have sex with men in Bangkok, Thailand, 2003–2007. J Acquir Immune Defic Syndr. 2010;53(2):234–9.
    1. The Ministry of Public Health HIV Situation Analysis Working Group . Impact analysis of HIV service delivery models. Paper presented at: The ending AIDS consultative meeting on the impact analysis for PrEP modelling; 2017. Aug 17; Nonthaburi, Thailand.
    1. Data Sheet Thailand [Internet] . Thailand: HIV AIDS Asia Pacific Research Statistical Data Information Resources AIDS Data Hub. 2016. [cited 2017 Nov 10].
    1. Blumenthal J, Haubrich R. Risk compensation in PrEP: an old debate emerges yet again. Virtual Mentor. 2014;16(11):909–15.
    1. Green D, Suraratdecha C, Manopaiboon C, Visavakum P, Monkongdee P, Kittinunvorakoon C, et al. The cost of a test and treat strategy for HIV among men who have sex with men and transgender women at five hospitals in Thailand. Dissemination meeting on the cost of PrEP and a test and treat strategy for HIV among men who have sex with men and transgender women in Thailand. Paper presented at: PrEP Costing Stakeholder Meeting; 2017. Mar 31; Nonthaburi, Thailand.
    1. World Bank national accounts data and OECD national accounts data files. [cited 2018 Mar 19]. Available from:
    1. World Health Organization . Choosing interventions that are cost‐effective. Geneva: World Health Organization; 2014.
    1. Ministry of Public Health . National strategy for ending AIDS epidemic in Thailand 2017–2030. Nonthaburi, Thailand: National AIDS Management Center, Department of Disease Control; 2017.
    1. Galárraga O, Wirtz VJ, Figueroa‐Lara A, Santa‐Ana‐Tellez Y, Coulibaly I, Viisainen K, et al. Unit costs for delivery of antiretroviral treatment and prevention of mother‐to‐child transmission of HIV: a systematic review for low‐ and middle‐income countries. Pharmacoeconomics. 2011;29(7):579–99. 10.2165/11586120-000000000-00000.
    1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.
    1. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre‐exposure prophylaxis for HIV prevention: a systematic review of cost‐effectiveness modelling studies. PLoS Med. 2013;10(3):e1001401.
    1. Mitchell KM, Lépine A, Terris‐Prestholt F, Torpey K, Khamofu H, Folayan MO, et al. Modelling the impact and cost‐effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. AIDS. 2015;29(15):2035–44.
    1. Cremin I, Morales F, Jewell BL, O'Reilly KR, Hallett TB. Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention. J Int AIDS Soc. 2015;18(4 Suppl 3):19946.
    1. Cremin I, McKinnon L, Kimani J, Cherutich P, Gakii G, Muriuki F, et al. PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study. Lancet HIV. 2017;4(5):e214–22.
    1. Cremin I, Hallett TB. Estimating the range of potential epidemiological impact of pre‐exposure prophylaxis: run‐away success or run‐away failure? AIDS. 2015;29(6):733–8.
    1. Jewell BL, Cremin I, Pickles M, Celum C, Baeten JM, Delany‐Moretlwe S, et al. Estimating the cost‐effectiveness of pre‐exposure prophylaxis to reduce HIV‐1 and HSV‐2 incidence in HIV‐serodiscordant couples in South Africa. PLoS ONE. 2015;10(1):e0115511.
    1. Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E, et al. Cost‐effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Clin Infect Dis. 2016;63(4):539–47.
    1. Moodley N, Gray G, Bertram M. The price of prevention: cost effectiveness of biomedical HIV prevention strategies in South Africa. Clin Res HIV AIDS. 2016;3(1):1031.
    1. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre‐exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS ONE. 2014;9(1):e86584.
    1. Long EF, Stavert RR. Portfolios of biomedical HIV interventions in South Africa: a cost‐effectiveness analysis. J Gen Intern Med. 2013;28(10):1294–301.
    1. Schneider K, Gray RT, Wilson DP. A cost‐effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia. Clin Infect Dis. 2014;58(7):1027–34.
    1. Nichols BE, Baltussen R, van Dijk JH, Thuma PE, Nouwen JL, Boucher CA, et al. Cost‐effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach. J Acquir Immune Defic Syndr. 2014;66(2):221–8.
    1. MacFadden DR, Tan DH, Mishra S. Optimizing HIV pre‐exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study. J Int AIDS Soc. 2016;19(1):20791.
    1. Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. A cost‐effectiveness analysis of preexposure prophylaxis for the prevention of HIV among los angeles county men who have sex with men. Clin Infect Dis. 2016;63(11):1495–504.
    1. Ross EL, Cinti SK, Hutton DW. Implementation and operational research: a cost‐effective, clinically actionable strategy for targeting HIV preexposure prophylaxis to high‐risk men who have sex with men. J Acquir Immune Defic Syndr. 2016;72(3):e61–7.
    1. McKenney J, Chen A, Hoover KW, Kelly J, Dowdy D, Sharifi P, et al. Optimal costs of HIV pre‐exposure prophylaxis for men who have sex with men. PLoS ONE. 2017;12(6):e0178170.
    1. Bernard CL, Owens DK, Goldhaber‐Fiebert JD, Brandeau ML. Estimation of the cost‐effectiveness of HIV prevention portfolios for people who inject drugs in the United States: a model‐based analysis. PLoS Med. 2017;14(5):e1002312.
    1. Adamson BJS, Carlson JJ, Kublin JG, Garrison LP. The potential cost‐effectiveness of pre‐exposure prophylaxis combined with HIV vaccines in the United States. Vaccines. 2017;5(2):13.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren